Van Eck Associates Corp Viking Therapeutics, Inc. Transaction History
Van Eck Associates Corp
- $80.1 Billion
- Q3 2024
A detailed history of Van Eck Associates Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 9,436 shares of VKTX stock, worth $398,671. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,436
Previous 16,279
42.04%
Holding current value
$398,671
Previous $863,000
33.95%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$430 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$255 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$197 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$89.4 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$79.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.24B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...